Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Mouse Biomarker Predicts Lethality of Human Prostate Cancer

By LabMedica International staff writers
Posted on 30 Jan 2019
Researchers have demonstrated the relevance of a prostate cancer biomarker found in a genetically engineered mouse model to the diagnosis and monitoring of the progress of the disease in humans.

Investigators at Rutgers University (New Brunswick, NJ, USA) reported in the December 5, 2018, online edition of the journal Nature Communications that they had elucidated cell-intrinsic drivers of metastatic prostate cancer progression through analyses of genetically engineered mouse models (GEMM) and correlative studies of human prostate cancer. More...
Expression profiling of lineage-marked cells from mouse primary tumors and metastases defined a signature of de novo metastatic progression.

Cross-species master regulator analyses comparing this mouse signature with a comparable human signature identified conserved drivers of metastatic progression with demonstrable clinical and functional relevance. In particular, nuclear receptor binding SET Domain Protein 2 (NSD2) was robustly expressed in lethal prostate cancer in humans, while its silencing inhibited metastasis of tumor transplants in mice.

These findings suggested that cross-species investigations based on analyses of de novo metastasis in GEMMs could be broadly used to elucidate mechanisms of metastatic progression and identify potential new therapeutic opportunities for treatment of lethal cancer.

"Currently, when a patient is diagnosed with prostate cancer, physicians can determine how advanced a tumor is but not whether the patients' cancer will spread," said contributing author Dr. Antonina Mitrofanova, assistant professor of biomedical and health informatics at Rutgers University. "If we can determine whether a patient's cancer is likely to spread at the time of diagnosis, we can start them on a targeted treatment plan as soon as possible to decrease the likelihood of their cancer spreading."

Related Links:
Rutgers University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.